Sina Haftchenary

653 total citations
25 papers, 389 citations indexed

About

Sina Haftchenary is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sina Haftchenary has authored 25 papers receiving a total of 389 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 10 papers in Molecular Biology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sina Haftchenary's work include Cytokine Signaling Pathways and Interactions (10 papers), Advanced Breast Cancer Therapies (8 papers) and Cancer Treatment and Pharmacology (5 papers). Sina Haftchenary is often cited by papers focused on Cytokine Signaling Pathways and Interactions (10 papers), Advanced Breast Cancer Therapies (8 papers) and Cancer Treatment and Pharmacology (5 papers). Sina Haftchenary collaborates with scholars based in Canada, United States and Germany. Sina Haftchenary's co-authors include Patrick T. Gunning, Katja Linher‐Melville, Gurmit Singh, Derek J. Wilson, Diana Resetca, Brent D. G. Page, Vijay Shahani, H. Artee Luchman, Kağan Kerman and Carly Griffin and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Sina Haftchenary

25 papers receiving 386 citations

Peers

Countries citing papers authored by Sina Haftchenary

Since Specialization

Citations

This map shows the geographic impact of Sina Haftchenary's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sina Haftchenary with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sina Haftchenary more than expected).

Fields of papers citing papers by Sina Haftchenary

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sina Haftchenary. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sina Haftchenary. The network helps show where Sina Haftchenary may publish in the future.

Co-authorship network of co-authors of Sina Haftchenary

This figure shows the co-authorship network connecting the top 25 collaborators of Sina Haftchenary. A scholar is included among the top collaborators of Sina Haftchenary based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sina Haftchenary. Sina Haftchenary is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2− Advanced Breast Cancer: Findings From a Multicountry Survey 2023 ·The Oncologist ·Fátima Cardoso, (unknown), Victoria Harmer, Nadia Harbeck, Ana Casas, Hope S. Rugo, Peter A. Fasching, Adam Moore, (unknown), (unknown), Sina Haftchenary, (unknown), Eva Schumacher-Wulf	8
2	Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison 2023 ·Therapeutic Advances in Medical Oncology ·Hope S. Rugo, Victoria Harmer, Joyce O’Shaughnessy, Komal Jhaveri, Sara M. Tolaney, Fátima Cardoso, Aditya Bardia, (unknown), (unknown), Sina Haftchenary, (unknown), Peter A. Fasching	8
3	Abstract P3-03-12: Risk of recurrence with adjuvant endocrine therapy in real world patients with hormone receptor positive/human epidermal growth factor receptor-negative early breast cancer: a US database analysis 2023 ·Cancer Research ·Joyce O’Shaughnessy, Denise A. Yardley, Lowell L. Hart, Pedram Razavi, Stephanie L. Graff, Jenifer Wogen, (unknown), (unknown), Sina Haftchenary, (unknown), Sara M. Tolaney	2
4	Abstract P5-13-25: PIK3CA registry: A noninterventional, descriptive, retrospective cohort study of PIK3CA mutations in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) 2022 ·Cancer Research ·Pathmanathan Rajadurai, Т. Yu. Semiglazova, (unknown), Fadi El Karak, Joanne Chiu, Sudeep Gupta, Hamdy A. Azim, (unknown), Antoine Arnaud, Sina Haftchenary, (unknown), (unknown), (unknown), Lyudmila Zhukova	1
5	178P Assessment of side effects (SEs) impacting quality of life (QoL) in patients (pts) undergoing treatment (tx) for advanced breast cancer (ABC) in clinical practice: A real-world (RW) multi-country survey 2022 ·Annals of Oncology ·Filipa Cardoso, (unknown), (unknown), (unknown), (unknown), Nadia Harbeck, Ana Casas, H. S. Rugo, Peter A. Fasching, Sina Haftchenary, (unknown), (unknown)	1
6	Quality of life (QOL) with ribociclib (RIB) plus aromatase inhibitor (AI) versus abemaciclib (ABE) plus AI as first-line (1L) treatment (tx) of hormone receptor-positive/human epidermal growth factor receptor–negative (HR+/HER2−) advanced breast cancer (ABC), assessed via matching-adjusted indirect comparison (MAIC). 2022 ·Journal of Clinical Oncology ·Hope S. Rugo, Joyce O’Shaughnessy, Komal Jhaveri, Sara M. Tolaney, Fátima Cardoso, Aditya Bardia, (unknown), (unknown), (unknown), Sina Haftchenary, Peter A. Fasching	2
7	326P Exploratory analysis of TreatER+ight: A Canadian prospective real-world observational study in HR+ advanced breast cancer 2020 ·Annals of Oncology ·C. T. Doyle, Theodore A. Vandenberg, Cristiano Ferrario, Nadia Califaretti, Nayyer Iqbal, Swati Kulkarni, Mihaela Mates, John Hilton, Nathaniel Bouganim, (unknown), Sina Haftchenary, (unknown), Stephen Chia	1
8	Chronic Inhibition of STAT3/STAT5 in Treatment-Resistant Human Breast Cancer Cell Subtypes: Convergence on the ROS/SUMO Pathway and Its Effects on xCT Expression and System xc- Activity 2016 ·PLoS ONE ·Katja Linher‐Melville, Mina G. Nashed, Robert G. Ungard, Sina Haftchenary, (unknown), Patrick T. Gunning, Gurmit Singh	19
9	Efficient Routes to a Diverse Array of Amino Alcohol-Derived Chiral Fragments 2016 ·ACS Combinatorial Science ·Sina Haftchenary, (unknown), Laura Furst, Sivaraman Dandapani, Steven Ferrara, Žarko Bošković, (unknown), (unknown), Juan Carlos Serrano, (unknown), (unknown), Jeffrey Mowat, Thomas Brumby, Marcus Bauser, Stuart L. Schreiber, Andrew J. Phillips	17
10	Carcinoembryonic Antigen Cell Adhesion Molecule 1 long isoform modulates malignancy of poorly differentiated colon cancer cells 2015 ·Gut ·Azadeh Arabzadeh, Jeremy Dupaul-Chicoine, Valérie Breton, Sina Haftchenary, (unknown), Claire Turbide, Maya Saleh, Kevin McGregor, Celia M.T. Greenwood, Uri David Akavia, Richard S. Blumberg, Patrick T. Gunning, Nicole Beauchemin	19
11	Signal transducer and activator of transcription 3 and 5 regulate system Xc- and redox balance in human breast cancer cells 2015 ·Molecular and Cellular Biochemistry ·Katja Linher‐Melville, Sina Haftchenary, Patrick T. Gunning, Gurmit Singh	43
12	Identification of Bidentate Salicylic Acid Inhibitors of PTP1B 2015 ·ACS Medicinal Chemistry Letters ·Sina Haftchenary, (unknown), Isabelle Aubry, Andrew M. Lewis, (unknown), Daniel P. Ball, (unknown), (unknown), Michel L. Tremblay, Patrick T. Gunning	17
13	Changes in Signal Transducer and Activator of Transcription 3 (STAT3) Dynamics Induced by Complexation with Pharmacological Inhibitors of Src Homology 2 (SH2) Domain Dimerization 2014 ·Journal of Biological Chemistry ·Diana Resetca, Sina Haftchenary, Patrick T. Gunning, Derek J. Wilson	39
14	Electrochemical detection of the Fc-STAT3 phosphorylation and STAT3–Fc-STAT3 dimerization and inhibition 2013 ·Molecular BioSystems ·Sanela Martić, (unknown), Sina Haftchenary, Vijay Shahani, (unknown), Daniel P. Ball, Patrick T. Gunning, Heinz‐Bernhard Kraatz	3
15	A 2,6,9-hetero-trisubstituted purine inhibitor exhibits potent biological effects against multiple myeloma cells 2013 ·Bioorganic & Medicinal Chemistry ·Vijay Shahani, Daniel P. Ball, (unknown), Zhihua Li, Paul A. Spagnuolo, Sina Haftchenary, Aaron D. Schimmer, Suzanne Trudel, Patrick T. Gunning	6
16	Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma 2013 ·ACS Medicinal Chemistry Letters ·Sina Haftchenary, H. Artee Luchman, (unknown), Anthony J. Veloso, Brent D. G. Page, Xin Cheng, (unknown), Natalie Grinshtein, Vijay Shahani, Kağan Kerman, David R. Kaplan, Carly Griffin, Asma M. Aman, Rima Al‐awar, Samuel Weiss, Patrick T. Gunning	93
17	Abstract C246: SH-4-54, a novel small-molecule inhibitor of STAT3, demonstrates significant anti-tumor activity against multiple myeloma. 2013 ·Molecular Cancer Therapeutics ·Zhihua Li, Sina Haftchenary, Danielle Croucher, Patrick T. Gunning, Suzanne Trudel	2
18	Inhibiting Aberrant Signal Transducer and Activator of Transcription Protein Activation with Tetrapodal, Small Molecule Src Homology 2 Domain Binders: Promising Agents against Multiple Myeloma 2013 ·Journal of Medicinal Chemistry ·Brent D. G. Page, Danielle Croucher, Zhihua Li, Sina Haftchenary, Víctor H. Jiménez‐Zepeda, Jennifer M. Atkinson, Paul A. Spagnuolo, (unknown), (unknown), Andrew M. Lewis, Aaron D. Schimmer, Suzanne Trudel, Patrick T. Gunning	30
19	Inhibiting aberrant Stat3 function with molecular therapeutics 2010 ·Anti-Cancer Drugs ·Sina Haftchenary, (unknown), Patrick T. Gunning	57
20	Binding interactions in early- and late-stage amyloid aggregates of TTR(105–115) 2009 ·Biophysical Chemistry ·(unknown), (unknown), Sina Haftchenary, Sylvie Morin, Derek J. Wilson	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact